Foram encontradas 20 questões.
4257816
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
( ) Students may compare how the article distinguishes clinical evidence, regulatory decisions and market expectations.
( ) The lesson may examine how international news circulates through English and influences access to scientific and economic information.
( ) Students should evaluate the therapeutic effectiveness of BPL-003 according to their personal experiences with mental-health treatments.
( ) The teacher may require students to distinguish information reported in the article from conclusions not supported by the text.
Mark the alternative that presents the CORRECT sequence.
Provas
Questão presente nas seguintes provas
4257815
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
- Interpretação de texto | Reading comprehension
- Gramática - Língua InglesaOrações condicionais | Conditional Clauses
- Gramática - Língua InglesaVerbos | VerbsPresente simples | Simple present
- Gramática - Língua InglesaVerbos | VerbsVerbos modais | Modal verbs
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
"Jefferies' Andrew Tsai estimates BPL-003 could generate sales of more than $1 billion to $2 billion if it succeeds in late-stage trials."
Consider the statements:
I. The modal verb could expresses a projected commercial possibility rather than a guaranteed result.
II. The clause introduced by if establishes a condition for the estimated sales performance.
III. The simple present form succeeds refers to a habitual event repeatedly observed in previous trials.
Mark the alternative that presents only the CORRECT statements.
Provas
Questão presente nas seguintes provas
4257814
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
Provas
Questão presente nas seguintes provas
4257813
Ano: 2026
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Disciplina: Inglês (Língua Inglesa)
Banca: AMEOSC
Orgão: Pref. Itapiranga-SC
Provas:
O texto seguinte servirá de base para responder à questão.
Lilly enters psychedelic drug race with up to $3.8
billion AtaiBeckley deal
July 16 (Reuters) - Eli Lilly (LLY.N) will buy AtaiBeckley
(ATAI.O) for up to $3.8 billion, the company said on
Thursday, joining a race among pharma majors to
develop psychedelic treatments for depression and other
mental health conditions.
The deal taps into rising interest in psychedelics following
easing regulations under the Trump administration and
reinforces Lilly's push to use windfall weight-loss drug
profits to diversify its product portfolio.
Lilly will gain access to AtaiBeckley's lead candidate
BPL-003, a psychedelic-based nasal spray in late-stage
development for treatment-resistant depression, a severe
form of the illness that does not improve after standard
treatments.
Jefferies' Andrew Tsai estimates BPL-003 could generate
sales of more than $1 billion to $2 billion if it succeeds in
late-stage trials. AtaiBeckley expects initial results from
the trials in early 2029.
Lilly will pay $6.75 per AtaiBeckley share in cash, a
premium of about 26% to the stock's closing price on
Wednesday. AtaiBeckley's shares rose more than 30% in
morning trading.
The offer consists of $2.8 billion upfront and up to $1
billion in milestone-based payments. The companies
expect the deal to close in the third quarter.
"The acquisition aligns with Eli Lilly's expanding
neuroscience portfolio and offers upside potential in large
markets like depression," said Barclays analyst Emily
Field.
Shares of psychedelic drug developers Enveric
Biosciences (ENVB.O) and GH Research (GHRS.O)
were up 6% and 11%, respectively.
The psychedelics industry could reach $12 billion in
revenue by 2034, rivaling the size of branded
antidepressants currently at about $8 billion, said RBC
Capital Markets analyst Trung Huynh.
SURGING INTEREST IN PSYCHEDELIC-BASED
THERAPIES
Drugmakers have shown growing interest in
psychedelic-based treatments for depression and other
mental health disorders.
President Donald Trump's executive order in April
directed U.S. health regulators to speed up reviews of
certain psychedelic treatments and increased federal
funding for research in the field.
AbbVie (ABBV.N) last year bought an experimental
psychedelic-based depression drug from Gilgamesh
Pharmaceuticals for up to $1.2 billion.
New York-based AtaiBeckley was formed through a
merger between Germany-based Atai Life Sciences and
privately held Beckley Psytech in 2025. Billionaire
venture capitalist Peter Thiel was an early backer of Atai.
Current medicines for treatment-resistant depression
include Johnson & Johnson's (JNJ.N) ketamine-derived
nasal spray Spravato — which requires twice-weekly
clinic visits — or other invasive interventions.
https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-enter
s-psychedelic-drug-race-with-up-38-billion-ataibeckley-deal-2026-07-16/
Consider the assertions:
I. The activity is compatible with a language-education approach that treats English as a means of accessing and critically examining international information.
BECAUSE
II. Students must analyse how linguistic choices and source positions influence the representation of a contemporary event.
Mark the CORRECT alternative.
Provas
Questão presente nas seguintes provas
A trajetória histórica de Itapiranga (SC) está relacionada
à ocupação e à organização territorial do Extremo Oeste
catarinense, processo que contribuiu para a formação de
características próprias do município. Sua localização e a
constituição do núcleo colonial que antecedeu sua
organização político-administrativa são elementos
relevantes para compreender a configuração do território
itapiranguense. Considerando os aspectos históricos e
geográficos de Itapiranga, analise as afirmativas a
seguir.
I.O município situa-se em área de fronteira com a Argentina e possui limite interestadual com o Rio Grande do Sul.
II.A colonização organizada na década de 1920 contou com famílias de descendência alemã vinculadas ao catolicismo.
III.A Sociedade União Popular participou da organização do processo colonizador que deu origem à colônia denominada Porto Novo.
IV.A colônia Porto Novo estava, naquele período, administrativamente vinculada ao município de São Miguel do Oeste.
Está correto o que se afirma em:
I.O município situa-se em área de fronteira com a Argentina e possui limite interestadual com o Rio Grande do Sul.
II.A colonização organizada na década de 1920 contou com famílias de descendência alemã vinculadas ao catolicismo.
III.A Sociedade União Popular participou da organização do processo colonizador que deu origem à colônia denominada Porto Novo.
IV.A colônia Porto Novo estava, naquele período, administrativamente vinculada ao município de São Miguel do Oeste.
Está correto o que se afirma em:
Provas
Questão presente nas seguintes provas
A Lei Orgânica de Itapiranga estabelece competências
municipais relacionadas à promoção de objetivos de
interesse coletivo e disciplina formas de atuação do
poder público junto a organizações da sociedade. Entre
essas competências, encontra-se a possibilidade de
destinação de recursos a determinadas entidades
privadas, desde que observadas as condições previstas
na legislação municipal. Considerando os requisitos
estabelecidos pela Lei Orgânica para essa finalidade, em
qual situação o Município poderá conceder o auxílio
financeiro previsto?
Provas
Questão presente nas seguintes provas
O enfrentamento de organizações criminosas recebeu
novo tratamento legislativo federal no primeiro semestre
de 2026, com uma norma sancionada que criou
categorias penais relacionadas à atuação de
organizações ultraviolentas, grupos paramilitares e
milícias privadas.
O texto considera práticas que, mediante violência ou grave ameaça, afetam a paz pública, a segurança coletiva ou instituições.
Entre as novas tipificações estão os crimes de _______________ e de _______________.
Identifique a alternativa que completa corretamente as lacunas acima.
O texto considera práticas que, mediante violência ou grave ameaça, afetam a paz pública, a segurança coletiva ou instituições.
Entre as novas tipificações estão os crimes de _______________ e de _______________.
Identifique a alternativa que completa corretamente as lacunas acima.
Provas
Questão presente nas seguintes provas
- OrtografiaPontuaçãoPonto de Exclamação e Interrogação
- OrtografiaPontuaçãoPonto e Vírgula
- SintaxeFrase, Oração e PeríodoOração CoordenadaOrações Coordenadas Sindéticas
- SintaxeFrase, Oração e PeríodoOração SubordinadaSubordinada Adjetiva
"O fato de podermos compartilhar esse espaço, de
estarmos juntos viajando não significa que somos iguais;
significa exatamente que somos capazes de atrair uns
aos outros pelas nossas diferenças, que deveriam guiar
o nosso roteiro de vida."
KRENAK, Ailton. Ideias para adiar o fim do mundo. São Paulo:
Companhia das Letras, 2019.
Assinale a opção que apresenta análise correta do texto.
Assinale a opção que apresenta análise correta do texto.
Provas
Questão presente nas seguintes provas
"Fomos, durante muito tempo, embalados com a história
de que somos a humanidade. Enquanto isso, enquanto
seu lobo não vem; fomos nos alienando desse
organismo de que somos parte, a Terra, e passamos a
pensar que ele é uma coisa e nós, outra: a Terra e a
humanidade."
KRENAK, Ailton. Ideias para adiar o fim do mundo. São Paulo:
Companhia das Letras, 2019.
Assinale a opção que apresenta análise correta do texto.
Assinale a opção que apresenta análise correta do texto.
Provas
Questão presente nas seguintes provas
"Quando retirei a faca da mala de roupas, embrulhada
em um pedaço de tecido antigo e encardido, com nódoas
escuras e um nó no meio, tinha pouco mais de sete
anos."
VIEIRA JUNIOR, Itamar. Torto Arado. São Paulo: Todavia, 2019.
(abertura do capítulo 1)
Assinale a opção que apresenta análise correta do texto.
Assinale a opção que apresenta análise correta do texto.
Provas
Questão presente nas seguintes provas
Cadernos
Caderno Container